Corporate Partnerships
We’re working together with our corporate partners to continually improve the supportive care of people with cancer. Below are some of the opportunities for your company to partner with MASCC:
Sponsor Our Annual Meeting
As the pre-eminent international and interdisciplinary conference on supportive care in cancer, the MASCC/ISOO Annual Meeting is a prime opportunity for your company to showcase products and treatments used to prevent and manage the adverse effects of cancer. For more information on sponsorship opportunities at the MASCC/ISOO Annual Meeting, please contact Melissa Chin, MASCC Executive Director, at mchin@mascc.org or Ruxandra Nedu, MASCC Associate Director, at rnedu@mascc.org.Corporate MASCC Membership
Corporate MASCC membership brings a variety of benefits, including exclusive privileges at the MASCC/ISOO Annual Meeting. These include:- Opportunities to meet exclusively with key MASCC opinion leaders
- Priority in the selection of dates for educational initiatives for MASCC members
- Priority in the selection of time slots for satellite symposia held in conjunction with the MASCC/ISOO Annual Meeting
- Six 2-year MASCC memberships with online access to Supportive Care in Cancer
- Discounted rates to the MASCC/ISOO Annual Meeting
- Significantly reduced costs for reviews of corporate-developed educational materials with commentary from MASCC specialists
- Opportunities to work with key MASCC opinion leaders to look at site-specific symptoms and prevention and management of treatment-induced side effects in cancer
- Advanced knowledge of the topics and issues facing MASCC members through the work of the study groups
Corporate Premium Members:
At Johnson & Johnson, we believe health is everything. Our strength in healthcare innovation empowers us to build a world where complex diseases are prevented, treated, and cured, where treatments are smarter and less invasive, and solutions are personal. Through our expertise in Innovative Medicine and MedTech, we are uniquely positioned to innovate across the full spectrum of healthcare solutions today to deliver the breakthroughs of tomorrow, and profoundly impact health for humanity. Learn more at https://www.jnj.com/ or at www.janssen.com/johnson-johnson-innovative-medicine.
For more information on the MARIPOSA study findings, please read our press releases from September 19, 2024, January 7, 2025, and March 26, 2025.
To learn more about the Phase 2 COCOON study, please visit the results from January 14, 2025 and from March 27, 2025.
For more than 15 years, La Roche-Posay has strived closely with dermatologists around the world, continually updating the scientific knowledge about skin side effects and providing safety-tested and efficient skincare solutions.
In 2023, La Roche-Posay gathered an international committee of experts (ISKIMO Board) including dermatologists, oncologists, radiotherapists, and nurses. By integrating all new oncology drugs while considering the unique characteristics of different skin colors, this collaboration generated an international dermocosmetic and drug algorithm (an atlas of solutions, available to healthcare professionals worldwide) to prevent and treat various skin side effects of cancer treatments.
In Addition, our program “Fight with Care” raises awareness on skin side effects and trains healthcare professionals and the general public to help patients, in addition to providing financial support and product donations.
For more information, please visit our website https://www.laroche-posay.com/
For more information about our learning session in supportive care, please visit: Cancer-support
The Novartis oncology strategy focuses on people living with cancer and those who
care for them, from loved ones to clinical care teams, including their providers. For
the past 30+ years, the aim has been to extend and improve lives by discovering
differentiated, innovative and practice-changing medicines for patients.
As Novartis reimagines medicine, it collaborates with a wide range of patient
advocacy groups and supports education, early cancer screening and diagnosis,
all while innovating at a rate that is unparalleled in the industry. With approximately
35 research and development projects across solid tumors, hematology and
radioligand therapy (RLT), Novartis is committed to using technology, leading
science and patient-centered research to deliver pioneering cancer care.
To learn more, visit https://www.novartis.com/us-en/
Corporate Members:
Gilead and Kite Oncology are working to transform how cancer is treated. We are innovating with next-generation therapies, combinations and technologies to deliver improved outcomes for people with cancer. We are purposefully building our oncology portfolio and pipeline to address the greatest gaps in care. From antibody-drug conjugate technologies and small molecules to cell therapy-based approaches, we are creating new possibilities for people with cancer.
For more information about Gilead Sciences and Kite, please visit https://www.gilead.com/ and https://www.kitepharma.com/
Advancing Supportive Care in Head and Neck Cancer: Multidisciplinary Patient-Centered Roundtable
On February 20, 2026, we were pleased to participate in a multidisciplinary, patient-centered roundtable focusing on advancing supportive care in head and neck cancer. With participation from global key opinion leaders, the evening included discussions on supportive care in locally advanced and metastatic cancer; the lived experience before, during, and after treatment; supportive care needs in emerging therapies, and more.
This event was a significant step forward in advancing the discussion on supportive care in head and neck cancer. We look forward to continuing to work together with our partners to ensure that all people affected by cancer receive excellent supportive care.
Event organized by the Multinational Association of Supportive Care in Cancer and hosted by Johnson & Johnson.